Company (location)

Company (location)

Value (M)

Type/product area

Terms/details

Date

NOVEMBER

Bind Therapeutics Inc. (Cambridge, Mass.)

Merck & Co. Inc. (Whitehouse Station, N.J.)

ND

Joint research and development agreement to discover and develop nanomedicines for oncology

The collaboration will leverage Bind's technology to create targeted Accurins based on payloads from Merck's preclinical oncology portfolio; the first two Merck compounds include a kinesin spindle protein inhibitor and a polo-like kinase 1 inhibitor; Bind will fund and conduct R&D activities to advance Accurin candidates based on the Merck agents through first-in-human studies; Merck and Bind then will alternate in choosing whether to advance the candidates; if Bind opts in, in most cases the company will not be obligated to payments to Merck beyond product royalties; if Merck opts in, the pharma will pay Bind a fee based on an undisclosed multiple of Bind's R&D expenses, plus royalties on product sales

11/7/14

Camurus AB (Lund, Sweden)

Braeburn Pharmaceuticals Sprl (Princeton, N.J.)

$151

Exclusive license deal for Camurus' weekly and monthly subcutaneous buprenorphine injection product to treat opioid addiction and pain

Braeburn obtains exclusive rights in North America and option rights in Japan, Korea, Taiwan and China, while Camurus retains all rights in the rest of the world; Camurus receives an up-front license fee of $20M, as well as $35M and $21M in development milestones for opioid dependence and pain, respectively; Camurus also is eligible to midteen royalties on Braeburn product sales and can receive up to an additional $75M in sales milestones

11/26/14

Cardiome Pharma Corp. (Vancouver, British Columbia)

Pharmacare Ltd. (part of the Aspen Group)

ND

Agreement to sell and distribute Brinavess (vernakalant intravenous) exclusively in South Africa

Aspen has agreed to specific annual commercial goals for the product but further financial details of the agreement were not disclosed

11/18/14

Celladon Corp. (San Diego)

Lonza Group (Basel, Switzerland)

ND

Agreement providing for the future commercial production of Mydicar, Celladon's enzyme replacement therapy for advanced heart failure that is currently in phase IIb development

The agreement follows a successful multiyear clinical manufacturing relationship and provides for initiation of pre-construction activities and the reservation of Lonza resources giving Celladon an opportunity to trigger construction of the dedicated facility and secure a long-term commercial supply arrangement

11/4/14

Ikaria Inc. (Hampton, N.J.)

Lee's Pharmaceutical Ltd. (Hong Kong)

ND

Strategic partnership for the registration and commercialization of Ikaria's Inomax Total Care package throughout the People's Republic of China, Hong Kong, Macau and Taiwan

Financial terms of the partnership were not disclosed

11/20/14

Sunshine Biopharma Inc. (Montreal)

Lonza Group Ltd. (Basel, Switzerland)

ND

Manufacturing deal for cancer drug Adva-271, a small-molecule topoisomerase II inhibitor that has demonstrated efficacy in killing several types of tumor cells

Financial terms were not disclosed

11/21/14

DECEMBER

Ariad Pharmaceuticals Inc. (Cambridge, Mass.)

Otsuka Pharmaceutical Co. Ltd. (Tokyo)

$77.5

Agreement to commercialize Ariad's Iclusig (ponatinib) in Japan and nine other Asian countries and to fund future clinical trials in those regions

Ariad will lead the completion of the Japanese new drug application (NDA), and Otsuka will file the NDA for regulatory approval in resistant and intolerant chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia in 2015; Ariad will get an up-front payment of $77.5M, a milestone payment upon approval in Japan in resistant and intolerant Philadelphia-positive leukemias and additional milestone payments for approval in other indications; Ariad also will receive a substantial share of net product sales

12/24/14

Ariad Pharmaceuticals Inc. (Cambridge, Mass.)

Angelini Pharma (parent firm of CSC Pharmaceuticals Inc.; Vienna)

$7.3

Agreement giving Angelini exclusive rights to commercialize Iclusig for the indications approved by the European Medicines Agency in Central and Eastern Europe

Terms calls for Angelini to cover sales and marketing, while Ariad will supply packaged drug; an up-front payment to Ariad and milestones associated with commercial launches will total about $7.3M; Ariad also is entitled to a share of sales

12/31/14

Gilead Sciences Inc. (Foster City, Calif.)

Mylan Laboratories Ltd. (Hyderabad, India; unit of Mylan Inc.)

ND

Nonexclusive rights agreement to manufacture and distribute Gilead's investigational antiretroviral drug tenofovir alafenamide, a therapy for HIV-1

The license extends to 112 countries, which together account for more than 30M people living with HIV, representing 84% of those infected globally

12/2/14

Nanotherapeutics Inc. (Alachua, Fla.)

Baxter International Inc. (Deerfield, Ill.)

ND

Agreement to sell its Vero cell technology and related assets, including its production facility in Bohumil, Czech Republic, to Nanotherapeutics

The agreement also includes investigational vaccine programs for Ross River virus, Chikungunya disease and West Nile virus

12/16/14

JANUARY

Egalet Corp. (Wayne, Pa.)

Luitpold Pharmaceuticals Inc. (Shirley, N.Y.)

$7

Acquisition agreement for Sprix (ketorolac tromethamine) nasal spray

Sprix is indicated for the management of moderate to moderately severe pain that requires analgesia at the opioid level; Egalet agreed to pay $7M and entered a six-month transition services agreement with Luitpold

1/9/15

Galmed Pharmaceuticals Ltd. (Tel Aviv, Israel)

Perrigo API Ltd. (subsidiary of Perrigo Co. plc; Dublin)

ND

Manufacturing services agreement for large-scale production of the active pharmaceutical ingredient of Galmed's aramchol

The API produced pursuant to that deal is expected to provide sufficient quantities of aramchol for Galmed's potential future phase III trials for the treatment of non-alcoholic steatohepatitis

1/29/15

Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Co. Ltd. (subsidiary of Hutchison China Meditech Ltd.; Hong Kong)

Astrazeneca (Wuxi) Trading Co. Ltd. (unit of Astrazeneca plc; London)

ND

Exclusive distribution agreement to distribute and market antipsychotic drug Seroquel (quetiapine) in China

Seroquel, which is approved for the treatment of schizophrenia and bipolar disorder, was launched in China in 2001

1/30/15

Melinta Therapeutics Inc. (New Haven, Conn.)

Eurofarma Laboratorios SA (Sao Paolo, Brazil)

$15

Commercialization and distribution agreements for delafloxacin, an investigational fluoroquinolone

Eurofarma will be responsible for obtaining regulatory approval in Brazil and will then have the right to market, sell and distribute delafloxacin in that country for the treatment of acute bacterial skin and skin structure infections; Melinta will receive a combined up-front cash and equity payment of $15M, as well as milestones and royalties on future sales of delafloxacin

1/9/15

FEBRUARY

Crystalgenomics Inc. (Seoul, South Korea)

Daewoong Pharmaceutical Co. Ltd. (Seoul, South Korea)

ND

Sales and marketing agreement for the commercialization of Acelex (polmacoxib) for osteoarthritis in Korea

Crystalgenomics, which will receive an up-front payment and milestone payments from Daewoong and will share profit from sales of the drug, said it now plans to pursue international partnerships to expand the market base for Acelex

2/10/15

Gilead Sciences Inc. (Foster City, Calif.)

Mylan Inc. (Pittsburgh)

ND

Agreement for exclusive distribution in India of Sovaldi and Harvoni to treat chronic hepatitis C

Mylan expects to begin distribution of Sovaldi in India in Q2; this new agreement is in addition to the licensing and technology transfer agreement that Mylan entered into with Gilead, which grants the non-exclusive rights to manufacture and distribute generic sofosbuvir, ledipasvir/sofosbuvir and, upon approval, the investigational NS5A inhibitor GS-5816 and single tablet regimen of sofosbuvir/GS-5816 in 91 developing countries

2/24/15

Tigenix NV (Leuven, Belgium)

Lonza Group AG (Basel, Switzerland)

ND

Agreement for the supply of Tigenix's adipose-derived stem cells product, Cx601

Lonza will manufacture material for the phase III trial of Cx601 in the U.S. at Lonza's cell therapy production facility in Walkersville, Md.; Cx601 is a locally injected suspension of allogeneic expanded eASCs for the treatment of complex perianal fistulas in Crohn's disease patients, currently in phase III in Europe

2/13/15

Twi Pharmaceuticals Inc. (Taipei, Taiwan)

Teva Pharmaceuticals Industries Ltd. (Jerusalem)

ND

Agreement that will transfer the U.S. sales and distribution rights of Twi's generic versions of Megace ES and Lidoderm from Teva to Twi

Twi will distribute both products through its wholly owned subsidiary, Twi Pharmaceuticals USA

2/25/15


Notes

The date indicated refers to the BioWorld Today issue in which the news item can be found.